v3.24.1.1.u2
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2024
Mar. 31, 2023
CURRENT ASSETS    
Cash and cash equivalents $ 5,441,978 $ 14,532,943
Deferred offering costs 277,827 0
Prepaid expenses and other current assets 505,983 557,623
TOTAL CURRENT ASSETS 6,225,788 15,090,566
Property and equipment, net 1,015,229 1,144,004
Right-of-use lease asset, net 883,054 1,151,909
Patents, net 1,100 1,650
Restricted cash 87,506 87,506
Deposits 33,305 33,305
TOTAL ASSETS 8,245,982 17,508,940
CURRENT LIABILITIES    
Accounts payable 777,862 432,889
Due to related parties 546,434 214,221
Lease liability, current portion 290,565 269,386
Other current liabilities 215,038 588,592
TOTAL CURRENT LIABILITIES 1,829,899 1,505,088
Lease liability, less current portion 649,751 939,642
TOTAL LIABILITIES 2,479,650 2,444,730
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY    
Common stock, $0.001 par value, 60,000,000 shares authorized at March 31, 2024 and 2023; 2,629,725 and 2,299,259 shares issued and outstanding at March 31, 2024 and 2023, respectively 2,629 2,299
Additional paid-in capital 160,337,371 157,426,606
Accumulated other comprehensive loss (6,940) (6,141)
Accumulated deficit (154,566,728) (142,358,554)
TOTAL AETHLON MEDICAL, INC. STOCKHOLDERS’ EQUITY BEFORE NONCONTROLLING INTERESTS 5,766,332 15,064,210
TOTAL STOCKHOLDERS’ EQUITY 5,766,332 15,064,210
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 8,245,982 $ 17,508,940

Source

10-K PDF
XBRL